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843FO-2 Relation of Myocardial Fibrosis to Circu lat ing 
Aldosterone and Endothelin in Primary and Secondary 
Human Hypertension: An Ultrasonic Study by Acoustic 
Densitometry 
Micheela Kozakova, Simona Buralli, Carlo Palombo, Angelica Moretti, Giampaolo 
Bernini, isabella Sudano, Stefano Taddei, Antonio Salvetti, Department of Internal 
Medicine, University Medical School, Pisa, Italy, CNR Institute of Clinical Physiology, 
Pisa, Italy. 
Myocardial fibrosis is found in the expadmental hypertensive heart and may be a major 
cause of heart failure in man. In experimental models, EndotheUn and Aldosterone were 
shown to act synergically in promoting myocardial fibrosis. 
Aim of the study was to investigate the possible relations between myocardial fibrosis as 
assessed by an advanced ultrasound technique (Acoustic Densitometry, AD, Agilent Tech- 
nologies), and circulating levels of Endothelin and Aldostsrone in pnmary and secondary 
hypertension. 
Methods: 32 patients (21 males; mean age 50±11; BP 159±9/101±7 mmHg), including 15 
with essential hypertension (EH), 7 with unilateral rano-vascular disease (RVH), 10 with pd- 
mary aldostaronism (PA), were studied, plasma Aldosterone (Aldo), Endothelin (Endo), 
Renin activity, and Hydroxyprolinuda were measured and related to LV mass and function 
(M-mode echo), as well as to the average myocardial Integrated Backscatter (IBS; riB), 
obtained by AD as an estimate of myocardial fibrosis. 
Results: All subjects had preserved LV systolic function. In PA and RVH patients, IBS and 
Aldo were higher (p<0.01) than in EH (IBS: 25±5 and 24±7 vs 18±4 dB; Aldo: 1.19¢0.7, 
1.18±0.5 and 0.64¢0.2 nmol/L), while Endo was increased only in PA (4.3¢-0.7 pg/ml vs 
3.7±0.7 and 3.1±0.8 in RVH and EH, p<0.01), In the overall population, IBS correlated 
directly to Aldo (r=0.41, p<0.02), Endo (r=0.57, p<0.01), Hydroxyprolinuda (r=0.47, p<0.01), 
LV mass (r=0.54, p<0.0f), disease duration (r--0.35, p<0.05). In multivariate analysis, Endo, 
Hydroxyprolinuda, LV mass and disease duration were independently related to IBS 
(adjusted R2=0.87, p<0.01 for all). LV mass was directly related to hydroxyprolinuda (r--0.51, 
p<0.01), but not to hormonal factors. Endo was directly related to LV end-diastolic diameter 
(r=0.37, p<0.05) and showed a trend to increase with increasing Aldo (R---0.32, p=0.07). 
Conclusions: in human hypertension, myocardial fibrosis partakes of the hypertrophic pro- 
cess, is related to disease duration and dependent on a synergic interaction of Endo and 
Aldo. The clinical models of pdmary and secondary hyperaldosteronism seem more prone to 
such a development han essential hypertension. 
9:00 a.m. 
843FO-3 Rofecoxib but Not Celecoxib Increases Systolic Blood 
Pressure in Hypertensive Patients Treated With Ace 
Inhibitors and Beta-Blockers 
William B. White, Andrew Wheiton, John G. Fort, University of Connecticut School of 
Medicine, Farmington, Connecticut, Johns Hopkins Universi~ Baltimore, Maryland. 
Background: The effects of celecoxib 200 mg/d and rofecoxib 25 mg/d on BP control were 
assessed in a randomized, double-blind study in elderly patients with osteoarthdtis on sta- 
ble (>3 months) antihypertensive therapy. 
Methods: 1092 patients received celecoxib (n=549) or rofecoxib (n=543) with their antihy- 
pertensive regimen for 6 weeks. Primary endpoints were changes in systolic and diastolic 
BP. Changes from baseline in SBP by type of antihypertensive therapy were analyzed 
using laast-square means based on baseline score, gender, race, and treatment. 
Results: Mean age was 73.2 yrs; 62% were women. There were no significant changes 
from baseline in mean SBP in the celecoxib arm for patients on any therapy. Significant 
increases in SBP were observed in the rofecoxib group when treated with ACEI, 13-block- 
ers, or these agents in combination with a diuretic (P<0.05). There were no changes from 
baseline in mean DBP in either COX-2 inhibitor arm. Calcium antagonists and diuretics had 
less interaction with either COX-2 specific inhibitor. Mean changes in SBP (mmHg) are 
shown: 
Antihypertensivetherapy by Mean change (SD), Adjusted LS Mean Pvalue 
class mm Hg Difference [95% el] 
Celecoxib Rofecoxib 
ACEi (n=161) -0.4 (12.7) 4.9 (13.3) -3.9 [-6.2 to -1.6] <0.001 
ACEI/dluretic (n=82) -1.0 (11.1) 2.8 (15.3) -3.1 [-6.1 to -0.1] 0.04 
B-Blocker (n=106) 1.1 (12.8) 4.9 (13.0) -2.9 [-5.7 to -0,2] 0.04 
8-Blockerldluretio (n=78) -1.2 (11.0) 4.9(14.3) -4.8 [-7.9 to -1.7] 0.003 
Calcium antagonist (n=114) 0.4 (11.4) 9.1 (11.6) 0.2 [-2.0 to 2.4] 0.87 
Cslclumantagoniet/dluretic -1.1 (10.2) 0.1 (12.8) -1.2[-4.0to1.5] 0.4 
(n=65) 
Conclusions: Data demonstrate that rofecoxib attenuates SBP control in patients on 
ACEI, 8-blocker alone and in combination with a diuretic but not on the calcium antago- 
nists. Furthermore, cetecoxib does not attenuate BP control in patients on any class of anti- 
hypertensive drugs. 
9:15 a.m. 
843FO-4  Eplerenone Reduces Proteinuria in Type II D iabetes 
Mellitus: Implications for Aldoaterone Involvement in 
the Pathogenesis of Renal Dysfunction 
Murrav Eostein, Vardaman Buckalew, Jorge Altamirano, Barbara Roniker, Scott Krause, 
Jay Kleiman, University of Miami School of Medicine, Miami, Flodda, Wake Forest 
University School of Medicine, Winston-Salem, North Carolina. 
Background: Aldosteronc may promote renal dysfunction. We investigated whether the 
selective aldosterone receptor antagonist (SARA) eplerenone reduces proteinuria in 
hypertensive patients with type II diabetes mellitus and albuminuria. 
Methods: After 2-4 wk on placebo, patients were randomized to foroed-titrated oses of 
eplerenone (Epl), enalapdl (Enl), or Epl and Enl in combination (Comb) for 24 wk. If DBP 
was >90 mm Hg at _> 8 wk, hydrochlorothiazide or amlodipine was added to control BP. 
The primary endpoint was the mean % change in urinary albumin to creatinine ratio 
(UACR) at 24 wk. Secondary endpoints were blood pressure (BP) changes and tolerabil- 
ity. 
Results: Epl reduced UACR by 62% vs 45% with Enl (p=0.015), and Comb was more 
effective (74%, p=0.018 vs Epl and p<0.001 vs Enl), BP decreases were not different 
between Epl and Enl (Table). Both drugs were well tolerated. No gynecomastia was 
reported. Incidence of K + _>6.0 mEq/L was Epl (8), Enl (2), and Comb (8). More patients 
were withdrawn because of sustained hyperkalemia in the Comb group (14) than in Epl 
(6) or Enl (2) groups. Other adverse events were similar among treatment groups. 
Conclusion: Differences in protainuria reduction despite similar BP Iowedng indicate 
that renal protection is independent of blood pressure reduction, consistent with the 
hypothesis that selective aldosterone antagonism is renoprotective. Further investigation 
will determine whether lower Epl doses reduce proteinuda with fewer K ÷ changes in dia- 
betic patients. 
Epl Enl Comb En110 mg/ 
(50 up to 200 mg) (10 up to 40 mg) Epl (50 up to 200 rag) 
(N=74) (N=74) (N=67) 
UACR (mg/g) at Baseline 611.4 483.3 470.9 
UACR at 24 wk 248.8 285.3 120.8 
BP at 24 wk (SBP/DBP) -19.5/-13.2* -20.4/-15.0 -21.8/-16.2 
(N=89) (N=83) (N=85) 
*p=0.015 vs Comb 
9:30 a.m. 
843FO-5 Effect of  Valsartan on Morbidity and Morta l i ty  in Heart  
Failure Patients With a History of Hypertension: Results 
From the Valsartan Heart Fai lure Trial 
N. J, Holwerda. Lionel Opie, Nancy Feliciano, Janet Bodner, on behalf of the VaI-HaFT 
Investigators, Sint Elisabeth Zeikechuis, Tilburg, The Netherlands. 
Background: Patients with hypertension commonly progress to heart failure (HF) 
despite treatment with currently recommended drugs. In the Valsartan Heart Failure Tdal 
(VaI-HeFT), morbidity risk was significantly reduced by 13.2% with valsartan (40-160 mg 
bid) compared to placebo (p=O,009), with similar all-cause mortality risk in the two 
groups. Risk for time to first HF hospitalization (with mortality censoring) was significantly 
reduced by 27.5% with valsartan (p<0,001), In the post-hoc analysis of VaI-HeFT 
patients, the effect of valsartan compared to placebo on outcomes in patients with a his- 
tory of hypertension (HTN) was investigated, 
Methods: VaI-HeFT was an international, multicenter, randomized, double blind trial in 
5010 patients with New York Heart Association (NYHA) class II-IV HF. History of HTN 
was defined as: pre-randomization systolic blood pressure (BP) _>140 mmHg or diastolic 
BP _>90, reported past medical history of HTN, or HTN reported as the primary etiology of 
HF. The primary efficacy outcomes were time to death and time to first morbid event 
(death, sudden death with resuscitation, hospitalization for HF, intravenous inotropic or 
vasodilator therapy >4 hours]. A secondary efficacy outcome was time to first HF hospi- 
talization. 
Results: A subgroup of 2372 patients had a documented history of HTN at baseline, 
1143 of whom were randomized to receive valsartan and 1229 to placebo. The effects of 
valsartan on morbidity and mortality in HF patients with (HTN+) and without (HTN-) a his- 
tory of HTN were generally consistent with the overall study population. The risk ratio 
(RR) of all-cause mortality for valsartan vs. placebo was 0.99 (95% CI 0.83, 1.18) in 
HTN+ and 1.05 (95% CI 0.88, 1.25) in HTN- patients. Risk of morbidity was lower for val- 
cartan than placebo in HTN+ (RR = 0.88, 95% CI 0.77, 1.02) and HTN- patients (RR = 
0.85, 95% CI 0.74, 0.99). The results were similar for the risk of first hospitalization for 
HF in HTN+ (RR = 0.76, 95% CI 0.83 - 0.93) and HTN- patients (RR = 0.69, 95% CI 0.57, 
0.84). 
Conclusion: Valcartan treatment has beneficial effects in the treatment of HF when 
added to prescdbed therapy in HF patients with or without a history of hypertension. 
artistically distinct therapeutic agents, simvastatin and PPART-agonist. The effects of the 
hypolipidemic simvastatin, confirm the sensitivity of MRI measurements, and the effects 
of the PPAR~agonist suggest a novel class of antiartedosclerotic ompounds. 
